1Heusinger-Ribeiro J,Fischer B,Goppelt-Struebe M,et al.Differential effects of simvastatin on mesangial cells.Kidney Int,2004,66(1):187-195.
2Massy ZA,Kim Y,Guijarro C,et al.Low-density lipoprotein-induced expression d interleukin-6,a marker d human mesangial cell inflammation:effects of oxidation and modulation by lovastatin.Biochem Biophys Res Commun,2000,267(2):536-540.
3Bussolati B,Deregibus MC,Fonsato V,et al.Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway.J Am Soc Nephrol,2005,16(7):1936-1947.
4Vieira JM Jr,Rodrigues LT,Mantovani E,et al.Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease.Nephron Physiol,2005,101(4):p82-91.
5Kwak B,Mulhaupt F,Myit S,et al.Statins as a newly recognized type of immunomodulator.Nat Med,2000,6(12):1399-1402.
6Nogaki F,Muso E,Yashiro M,et al.Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells.Kidney Int Suppl,1999,71:S198-S201.
7Tonelli M,Sacks F,Pfdfer M,et al.Biomarkers of inflammation and progression of chronic kidney disease.Kidney Int,2005,68:237-245.
8Gueler F,Rong S,Park JK,et al.Postischemic Acute Renal Failure Is Reduced by Short-Term Statin Treatment in a Rat Model.J Am Soc Nephrol,2002,13(9):2288-2298.
9Mulhaupt F,Matter CM,Kwak BR,et al.Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.Cardiovasc Res,2003,59(3):755-766.
10Skoglund B,Fourslund C,Aspenberg P.Simvastatin Improves Fracture Healing in Mice.J Bone Miner Res,2002,17(11):2004-2008.
3Hass M. Histologic subclassificatiom of IgA nephropathy: A clin-icopathologic study of 244 cases. Am J Kidney Dis, 1997,29:829-842.
4Asaba K,Tojo A, Onozato ML, et al. Long-term renal prognosisof IgA nephropathy with therapeutic trend shifts. Intern Med,2009,48:883.
5Kawamoto S,Kawamura T,Miyazaki Y,et al. Effects of atorvas-tatin on hyperlipidemia in kidney disease patients. Nippon J inzoGakkai Shi,2007,49:41-48.
6Yagi S, Aihara K, Ikeda Y, et al. Pitavastatin, an HMG-CoA re-ductase inhibitor, exerts eNOS-independent protective actions a-gainst angiotensin H induced cardiovascular remodeling and renalinsufficiency. Circ Res,2008,102:68-76.
7Buemi M,Senatore M,Corica F,et al. Statins and progressive re-nal disease. Med Res Rev, 2002,22,76-84.
8Kostapanos MS,Milionis HJ, Elisaf MS. An overview of the ex-tra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther,2008,13:157-174.
9Sharyo S, Yokota-Ikeda N, Mori M, ct al. Pravastatin improvesrenal ischemia-reperfusion injury by inhibiting the mevalonatepathway. Kidney Int, 2008,74 : 577-584.
10Kokubo T,Ishikawa N,Uchida H,et al. CKD Accelerates Devel- opment of NeointimalHyperplasia in Arteriovenous Fistulas. J Am Soc Nephrol,2009,20 (6) : 1236 - 1245.
